Neuropathix Revenue and Competitors

Doylestown, PA USA

Location

$4.5M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Neuropathix's estimated annual revenue is currently $603k per year.(i)
  • Neuropathix's estimated revenue per employee is $100,500
  • Neuropathix's total funding is $4.5M.

Employee Data

  • Neuropathix has 6 Employees.(i)
  • Neuropathix grew their employee count by -14% last year.

Neuropathix's People

NameTitleEmail/Phone
1
Chairman & CEOReveal Email/Phone
2
CFOReveal Email/Phone
3
Founder, CCOReveal Email/Phone
4
CSOReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$46.6M2328%N/AN/A
#2
$84.2M4193%N/AN/A
#3
$14.1M700%N/AN/A
#4
$1224.3M6091-9%N/AN/A
#5
$43.2M215-4%N/AN/A
#6
$12.3M61-6%N/AN/A
#7
$19.9M9941%N/AN/A
#8
$16.5M82-5%N/AN/A
#9
$97.7M48630%N/AN/A
#10
$12.5M62-16%N/AN/A
Add Company

What Is Neuropathix?

Neuropathix is a biopharmaceutical company focused on the research and development of a pipeline of next generation socially responsible pain management therapeutics to treat patients with significant unmet medical needs.

keywords:N/A

$4.5M

Total Funding

6

Number of Employees

$603k

Revenue (est)

-14%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Neuropathix News

2022-04-06 - 2022-04-13 | OTCQB:NPTX | Press Release | Neuropathix Inc

Neuropathix, Inc. Highlights Positive Preclinical Study Results on Lead Drug Candidate KLS-13019. NPTX | 10 days ago.

2022-04-06 - Neuropathix, Inc. Highlights Positive Preclinical Study Results ...

Neuropathix, Inc. Highlights Positive Preclinical Study Results on Lead Drug Candidate KLS-13019. By. ACCESSWIRE.

2022-03-30 - Medical Marijuana, Inc. Provides Update on its Pharmaceutical Initiatives

Neuropathix (OTCQB: NPTX), a major investment of Medical Marijuana, Inc. and a socially responsible pain management life sciences company,...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.6M6N/AN/A
#2
$0.4M620%N/A
#3
$0.5M70%N/A
#4
$0.6M860%N/A
#5
$0.7M9-10%N/A